Ventripoint Performs Live Demonstrations of the Next-Generation VMS+ System at EuroEcho 2018

Toronto, Ontario, December 14, 2018 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company", TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it showcased the VMS+ 3.0 System at EuroEcho 2018 in Milan, Italy, one of the world's largest cardiovascular imaging congress' with 4,200 attendees.

Each year the EuroEcho Congress attracts world-renowned global experts in the field of cardiovascular imaging providing an excellent venue to deliver live demonstrations of the new VMS+ 3.0 System. The Ventripoint team presented over 80 hands-on demonstrations during the three-day conference in Milan with positive feedback from leading cardiologists. With its smaller footprint and an improved user interface, the VMS+ 3.0 allows for superior integration into the clinical echocardiography workflow and environment. The system is designed to use Artificial Intelligence (AI) to provide a streamlined approach for volumetric measurements and ejection fractions for all 4 chambers of the heart from standard 2D echo images. The 3D guidance tracking system has also been replaced with an innovative tracking sensor technology to enable patient repositioning during the examination.

During the congress, Dr. Shelby Kutty, newly appointed professor of pediatrics and cardiology at Johns Hopkins School of Medicine, presented a poster on a comparative study performed with the VMS+ System at the University of Nebraska Medical Center Children's Hospital; "Application of knowledge-based reconstruction to three dimensional echocardiography and comparison with semiautomatic border detection method for evaluating ventricular function".

"This study presented at EuroEcho 2018, demonstrates the clinical feasibility of quantifying right and left ventricular volumes and function using VMS+ on two and three dimensional images acquired from multiple cardiac ultrasound systems. This included normal and repaired Tetralogy of Fallot hearts. The experience shows the possibilities of extension of VMS+ technology to the 3D echocardiography realm and indicates its value for a wide spectrum of heart diseases. We were pleased with the outcomes and look forward to future collaborations with Ventripoint" commented Dr. Kutty.

"From conference seminars, poster presentations and discussions with key opinion leaders in the Ventripoint exhibit booth, it is clear there is a significant need for a cost-effective and accurate approach for volumetric measurements of all 4 chambers of the heart. We have secured a number of follow-up meetings for 2019 after the successful turnout at the congress. The VMS+ technology sets us apart and can make a valuable difference in patient outcomes" notes Mehran Mehrtash, Vice-President, Worldwide Distributor Sales of Ventripoint Diagnostics.

The VMS+ 3.0 System is not commercially available for sale and is for investigational use only.

About Ventripoint Diagnostics Ltd.

Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

For further information, please contact:
Dr. George Adams, CEO
Telephone: (519) 803-6937
Email: gadams@ventripoint.com

Forward Looking Statements:

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.